NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

$141.82
+2.83 (+2.04%)
(As of 11:14 AM ET)
Today's Range
$141.78
$146.22
50-Day Range
$129.52
$179.69
52-Week Range
$126.97
$266.67
Volume
76,385 shs
Average Volume
255,567 shs
Market Capitalization
$13.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$251.70

BeiGene MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
74.2% Upside
$251.70 Price Target
Short Interest
Bearish
1.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of BeiGene in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$10.22 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.87) to ($2.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

Medical Sector

635th out of 909 stocks

Pharmaceutical Preparations Industry

287th out of 423 stocks

BGNE stock logo

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

BGNE Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
BeiGene (NASDAQ:BGNE) Trading Down 2.4%
BeiGene Becomes Oversold (BGNE)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
4 Analysts Assess BeiGene: What You Need To Know
BGNE Apr 2024 140.000 put
BGNE Apr 2024 220.000 call
BGNE Apr 2024 125.000 put
BGNE Apr 2024 180.000 call
BGNE Apr 2024 135.000 put
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/24/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BGNE
Fax
N/A
Employees
10,600
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$251.70
High Stock Price Target
$345.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+75.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-881,710,000.00
Pretax Margin
-33.59%

Debt

Sales & Book Value

Annual Sales
$2.46 billion
Book Value
$37.10 per share

Miscellaneous

Free Float
88,563,000
Market Cap
$13.72 billion
Optionable
Optionable
Beta
0.61

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • BeiGene, Ltd. has a diverse portfolio of oncology medicines, including advanced treatments like BRUKINSA and TEVIMBRA, which cater to a wide range of cancers.
  • The company is actively developing a pipeline of innovative inhibitors and antibodies, such as Sonrotoclax and Zanidatamab, which shows promising potential for future growth.
  • Collaborations with reputable companies like Amgen Inc. and Novartis AG indicate strong partnerships that could lead to further advancements and market opportunities.
  • BeiGene, Ltd. has a global presence, engaging in the development and commercialization of oncology medicines worldwide, providing exposure to diverse markets.
  • Considering the recent positive market sentiment towards the pharmaceutical industry, BeiGene, Ltd. could benefit from favorable industry trends.

Cons

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • Market volatility and regulatory challenges in the pharmaceutical industry could impact the company's growth trajectory and stock performance.
  • Competition in the oncology medicines market is intense, with established players and new entrants posing a threat to BeiGene, Ltd.'s market share.
  • Investing in pharmaceutical companies like BeiGene, Ltd. carries inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new products.
  • The current stock price of BeiGene, Ltd. may be influenced by various factors, including market conditions, industry news, and company-specific developments, which could lead to fluctuations in share value.
  • Global economic uncertainties and geopolitical factors may impact the demand for oncology medicines and affect BeiGene, Ltd.'s financial performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings
or view top-rated stocks.

What is BeiGene's stock price target for 2024?

9 brokers have issued twelve-month price targets for BeiGene's stock. Their BGNE share price targets range from $161.00 to $345.00. On average, they predict the company's stock price to reach $251.70 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price.
View analysts price targets for BGNE
or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2024?

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE shares have decreased by 19.9% and is now trading at $144.47.
View the best growth stocks for 2024 here
.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BGNE earnings forecast
.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Monday, February, 26th. The company reported ($3.53) earnings per share for the quarter, beating analysts' consensus estimates of ($3.61) by $0.08. The firm had revenue of $634.40 million for the quarter, compared to analysts' expectations of $632.52 million. BeiGene had a negative trailing twelve-month return on equity of 23.12% and a negative net margin of 35.86%. The firm's revenue was up 66.9% on a year-over-year basis. During the same period in the prior year, the business posted ($4.29) EPS.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a number of institutional and retail investors. Top institutional investors include Venturi Wealth Management LLC (0.00%) and LVW Advisors LLC (0.00%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends
.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners